Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) should contact The Gross Law Firm about pending Class Action - MLTX

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) for allegedly issuing false and misleading statements regarding its drug candidate SLK during the class period from March 10, 2024, to September 29, 2025 [1]. Summary by Sections Allegations - The complaint alleges that the defendants failed to disclose that SLK and BIMZELX share the same molecular targets, specifically the inflammatory cytokines IL-17A and IL-17F [1]. - It is claimed that SLK's unique Nanobody structure would not provide a clinical benefit over the traditional monoclonal structure of BIMZELX [1]. - The assertion is made that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy [1]. - Based on these points, the defendants are said to lack a reasonable basis for their positive statements regarding SLK's superiority to monoclonal antibodies [1]. Class Action Details - Shareholders who purchased shares of MLTX during the specified class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1]. - The deadline for shareholders to register for the class action is December 15, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3].